Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
April 21, 2020– In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 – – Live…Immunic, Inc. Announces Changes to Executive Team
April 17, 2020NEW YORK, April 17, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements
March 15, 2020– Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 – – Cash of…Immunic, Inc. to Participate in Scientific and Investor Conferences in February
February 11, 2020NEW YORK, February 11, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
January 8, 2020Phase 1 Clinical Studies to begin in First Half of 2020 NEW YORK, January 8, 2020 – Immunic, Inc. (Nasdaq: IMUX), a…